Asian Pacific Journal of Allergy and Immunology

  • HOME
  • ABOUT
  • EDITORS
  • SUBMISSION
    • Online Submission
    • Author Instructions
  • ISSUE
    • Current
    • Early Online
    • Archives
  • PERMISSIONS
  • CONTACT
  • ADVERTISE
Home
 / 
Early Online
 / 
Ability of Alere™ HIV Combo to diagnose acute HIV infection is based mainly on HIV-1 p24 antigen detection

November 2, 2021

Ability of Alere™ HIV Combo to diagnose acute HIV infection is based mainly on HIV-1 p24 antigen detection

Sunee Sirivichayakul,1 Tippawan Pankam,2 Supanit Pattanachaiwit,2 Kannapat Phancharoen,2 Napapat Barisri,2 Supphachoke Areeyolwattana,2 Nittaya Phanuphak,3,4 Praphan Phanuphak1,3

1 Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
2 Thai Red Cross Anonymous Clinic Laboratory, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
3 Institute of HIV Research and Innovation (IHRI), Bangkok, Thailand
4 Center of Excellence in Transgender Health (CETH), Chulalongkorn University, Bangkok, Thailand

Abstract

Background: Alere™ HIV Combo is the only rapid and sensitive point-of-care 4th generation (antigen/antibody) HIV test newly available in Thailand which is advantageous of differentiating between positivity of antigen or antibody or both, especially in acute HIV infection (AHI). AHI in this study was defined by positive machine-based 4th generation test with measurable HIV-RNA but negative 3rd generation (IgM/IgG antibody only) tests.
Objective: To evaluate the performance characteristics of Alere™ HIV Combo.
Methods: Fifty stored plasma samples of subjects diagnosed with AHI were used to evaluate Alere™ HIV Combo.
Results: Of the 50 AHI samples, Alere™ HIV Combo was positive in 37 (74%): 5 with antibody positive only (R1), 26 with p24 antigen positive only (R2), and 6 with both p24 antigen and antibody positive (R3). Mean sample/cut-off (S/CO) ratios from machine-based 4th generation test of R1, R2 and R3 were 21.55, 148.38 and 72.97 respectively as compared to 7.57 for the 13 non-reactive (NR) samples. The corresponding median log10 HIV-RNA of NR, R1, R2 and R3 were 5.59, 5.86, 7.00 and 6.61 copies/mL respectively. R2 and R3 had significantly higher S/CO and HIV-RNA than NR and R1. Alere™ HIV Combo detected mainly p24 antigen in AHI as seen in 32/50 (64%) subjects and could detect 11/50 (22%) antibody in AHI samples which were missed by the two 3rd generation HIV tests used in our testing algorithm.
Conclusions: Alere™ HIV Combo is the ideal screening test in a setting with high AHI where machine-based 4th generation test is not available.
Key words: rapid 4th generation HIV test, acute HIV infection, p24 antigen, Alere™ HIV Combo, Rapid distinguishable antigen-antibody HIV test

Full Text
acute HIV infection, Alere™ HIV Combo, p24 antigen, rapid 4th generation HIV test, Rapid distinguishable antigen-antibody HIV test

Categories

  • Announcement (1)
  • Case Report (23)
  • Early Online (93)
  • Original Article (223)
  • Review Article (29)

Key words

allergen Allergic rhinitis Allergy Anaphylaxis Asthma atopic dermatitis child Children Chlorhexidine chronic rhinosinusitis chronic spontaneous urticaria Chronic Urticaria COVID-19 cytokine depression diagnosis drug allergy Drug hypersensitivity efficacy Epidemiology food allergy Food hypersensitivity house dust mite IgE Immunotherapy obstructive sleep apnea Omalizumab prevalence primary immunodeficiency Quality of life Questionnaire Reliability risk factor risk factors safety SARS-CoV-2 Sensitization Severe asthma Skin prick test Specific IgE Thai treatment urticaria vaccine Vitamin D
Asian Pacific Journal of Allergy and Immunology

Support Contact

Managing Editor
Ms. Patrawadee Pitakpolrat
E-mail: managingeditor@apjai-journal.org

Production Editor
Ms. Chanita Jangsawang
E-mail: chanita.j@apjai-journal.org

Asian Pacific Journal of Allergy and Immunology © 2025 All rights reserved.
All rights reserved | Privacy Policy